Please complete the CAPTCHA to continue
@vivocapital.com
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
Priscilla S. is listed as Biotech Investor | Principal at Vivo Capital | MD/MBA at Vivo Capital, based in San Francisco, California, United States. AeroLeads shows a work email signal at vivocapital.com and a matched LinkedIn profile for Priscilla S..
Priscilla S. previously worked as Principal at Vivo Capital and Board Member at Inspirna, Inc.. Priscilla S. holds Master Of Business Administration (M.B.A.) from Stanford University Graduate School Of Business.
This section adds company-level context without repeating Priscilla S.'s masked contact details.
AeroLeads found 1 current-domain work email signal for Priscilla S.. Compare company email patterns before reaching out.
I am a healthcare investor with 8 yrs experience in the buyside and 13 years experience in healthcare. currently focusing on early and growth-stage biopharma (and revenue-stage medical device to a lesser extent) opportunities.I am a physician by training and have experiences in all stages of investing (VC/PE: early, growth, crossover, and late-stage investing) across different asset classes/deal structures (equity, convertible bond, royalty/revenue-interest/debt financing), geography (US, Europe, cross-border investing with China, South Korea), and healthcare sectors (digital health, medtech, and biopharma).Also experienced in company creation and incubation (joint venture and NewCo), corporate development/M&A, fundraising (crossover, NASDAQ and HKEX IPO prep), drug discovery (academia), and business development (partnership/licensing).
Listed skills include Research, Biochemistry, Cell Culture, Molecular Biology, and 40 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
Palo Alto, Ca, Us
Vivo Capital is a $7B AUM healthcare-focused investment firm. We are currently investing out of 3 vehicles: our flagship fund IX (late-stage VC, growth, PE) of $1.6B, Innovation Fund II (VC) of ~$330M, and opportunity fund (long-only public vehicle) of $~700M.
Singapore, Sg
CBC Group (fka C-Bridge Capital) is a healthcare-dedicated private equity firm with $4.7B of AUM focused on platform-building and buyout investment opportunities across three core areas: biopharma, medtech, and healthcare services. Its flagship strategy features an operationally intensive approach. Its representative investment, includes: I-Mab Biopharma (NASDAQ: IMAB), Everest Medicines (HKEX:1952.HK), among others. CBC also manages a complementary private credit strategy (Royalty Bridge Fund/RBF) dedicated to provide alternative non-dilutive financing to healthcare companies backed by royalties, revenue interest, and other cash flows generated by the sale of healthcare products and services. I was involved in the fund creation, strategy, fundraising, and initial capital deployment.Deals and boards involvement includes (but not limited to): - Everest Medicines (HKEX:1952.HK)- company creation/Series A and Series B. Board observer- AffaMed Therapeutics (Private)- company creation/ JV turned to licensing agreement with Samsung Bioepis/Series A and merger with EverInsight. Board observer- Graybug Vision (NASDAQ: GRAY)- $80M crossover. Boad observer- Paratek (NASDAQ: PRTK)- $60M royalty/credit deal
New York, Ny, Us
Part of the founding investor (incubated by CBC group) and team member. Involved in various roles and phases of the company start-up. Worked closely with C-suite (CEO, CFO, CBO, President, etc) and board directors in business development (involved in Immunomedics Trodelvy deal among others), strategy, and financing (series A to crossover to IPO).Everest (1952.HK) was listed in HKEX in 2020 at US$2.7B valuation, just under 3 years since inception in 2017. Prior to the listing, Everest had raised money in private market from top tier investors including: RA Capital, Hillhouse Capital, Decheng Capital, Cormorant, Janus Henderson, Rock Springs Capital, and HBM, to name a few.
Boston, Ma, Us
Flare Capital is a team of proven healthcare technology venture capital investors who raised one of the industry’s largest dedicated venture capital funds focused exclusively on early stage and emerging growth investments in healthcare technology innovation.https://www.flarecapital.com/our-team
Quick answers generated from the profile data available on this page.
Priscilla S. works for Vivo Capital.
Priscilla S. is listed as Biotech Investor | Principal at Vivo Capital | MD/MBA at Vivo Capital.
AeroLeads has found 1 work email signal at @vivocapital.com for Priscilla S. at Vivo Capital.
Priscilla S. is based in San Francisco, California, United States while working with Vivo Capital.
Priscilla S. has worked for Vivo Capital, Inspirna, Inc., Nighthawk Therapeutics, Clasp Therapeutics, and Bonum Therapeutics.
You can use AeroLeads to view verified contact signals for Priscilla S. at Vivo Capital, including work email, phone, and LinkedIn data when available.
Priscilla S. holds Master Of Business Administration (M.B.A.) from Stanford University Graduate School Of Business.
Priscilla S. is listed with skills including Research, Biochemistry, Cell Culture, Molecular Biology, Western Blotting, Cell, Neuroscience, and Cancer.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts